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To the Editor: We highly appreciate Dr Carstensen’s interest
[1] in our study [2]. With regard to the first question, HRs
are not reported per year but refer to the total period of
exposure. We referred to an earlier paper from one of us in
which an example on thiazide diuretics and hip fracture is
described to explain how we usually analyse drug exposure
as a time-dependent variable with categories for different
durations of use [3]. On reading the first question by Dr
Carstensen [1], we realise that the reference may have been
confusing because in the current study we made a direct
comparison between insulin glargine (A21Gly,B31Arg,
B32Arg human insulin), other insulin analogues and human
insulin in which, at the moment a tumour was diagnosed, the
insulin exposure status (insulin glargine, human analogues or
human insulin) in those diagnosed with cancer was compared
with the exposure status of the remainder of the cohort mem-
bers at the same day of follow-up since starting on insulin. In
this way, our HR of 0.7 was an overall HR.
The second question concerns the assumption of equality
of risks of cancer at initiation. As all cohort members were
followed as of their first use of insulin after earlier use of
oral glucose-lowering drugs, the assumption that their can-
cer risk at start of follow-up is more or less similar does not
seem unrealistic. Although one can never exclude the
chance of ‘confounding by indication’ with these drugs in
the treatment of diabetes mellitus, with regard to the risk of
cancer, few doctors will prefer one type of insulin over the
other in people without known cancer (the situation in our
study population at baseline) as all insulin types are sus-
pected as potentially carcinogenic because of their growth-
promoting properties. Moreover, we adjusted for baseline
differences where possible. However, to address the con-
cerns of Dr Carstensen, we performed another sensitivity
analysis. We included an additional variable in the model
indicating whether a participant used insulin glargine at
baseline (yes/no) and another variable indicating whether a
participant used other insulin analogues at baseline (yes/no).
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DOI 10.1007/s00125-011-2448-2These additional analyses did not change the point estimates:
for insulin glargine an HR of 0.75 was found (95% CI 0.71,
0.79)andforotherinsulinanaloguesanHRof0.85wasfound
(95% CI 0.81, 0.88) in comparison with human insulin. This
does not surprise us, as adjustment for propensity scores also
did not change our results. However, we concluded that a risk
difference at baseline cannot be excluded, partly because an
intention-to-treat(‘fixed’)analysisalsoshowedalowerriskof
cancer in users of insulin glargine.
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